💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tyloxapol

CHEMBL1201548 Phase 4 承認済み Unknown
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type that acts as a mucolytic and surfactant, reducing surface tension in respiratory secretions to facilitate mucociliary clearance. It is used as a respiratory adjunct to thin and mobilize viscous bronchial secretions in conditions such as bronchitis, asthma, and postoperative atelectasis. It has also been used as a pharmaceutical excipient to disperse poorly water-soluble substances.

作用機序

Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type that acts as a mucolytic and surfactant, reducing surface tension in respiratory secretions to facilitate mucociliary clearance. It is used as a respiratory adjunct to thin and mobilize viscous bronchial secretions in conditions such as bronchitis, asthma, and postoperative atelectasis. It has also been used as a pharmaceutical excipient to disperse poorly water-soluble substances.

Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

Yes, Tyloxapol is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201548. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.